This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026
The previous summary described this only as an emergency-treatment label. We now distinguish Gvoke's severe-hypoglycemia indication from Gvoke VialDx's diagnostic indication in the same cited label. 1
What this version reported
The cited label describes subcutaneous Gvoke for severe hypoglycemia in people with diabetes aged two years and older, and intravenous Gvoke VialDx as a diagnostic aid in adults. The product, route and indication must remain distinct.↗
Organizations named in cited records:
- U.S. National Library of Medicine↗
Sources for this version
- 1GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026